The Cure Institute Project has created an online funding campaign aiming at the collection of over 25 thousand reais to cover the initial expenses of the phase III of the Neosamba research, which focus is to reduce the relapsing risks of a certain type of breast cancer. Click here http://vaka.me/743320 to contribute.
About the research:
Every year new cases of cancer are recorded in Brazil. According to the most recent data published by the National Institute of Cancer (INCA), up to December 2019, 60 thousand individuals will be diagnosed with that disease. How can we revert that scenario? Specialists of the area are convinced that such reversion can be achieved through clinical research due to increased access to new therapies, improved quality of life and increased survival among patients. With that in mind, physicians and members of the civil society have gathered to encourage the production of new studies in Brazil.
One result of such union is the partnership between the Cure Project and 12 oncological centers installed in 8 Brazilian states. All partners are searching for financial support to launch the phase III of Neosamba, which objective is to find a way to prevent relapses of the negative HER-2 breast cancer.
During the 2018 edition of the ASCO, the congress of the American Society of Clinical Oncology, the physician José Bines was present to address the conclusion of the phase II of the Neosamba research. Conducted by INCA, the research investigated 118 patients, with the objective of assessing if a change in the order of drugs of the anthracycline and taxane classes (these are the two drugs most commonly used for chemotherapy of breast cancer) would result in increased survival/ among the patients.
The findings of the study suggest that treating the patients initially with taxane and subsequently with anthracycline, instead of the opposite order prescribed in the previous treatment standard, could result in significative gains in progression-free survival, and mainly, global survival.
The study is heading to phase III, when the research will investigate a larger number of patients during a longer time. However, there are no financial resources to launch that phase, which is defined by the oncologist José Bines as a “scientific confirmatory study”.
The results of that analysis can result in a most effective treatment of neoadjuvant chemotherapy (delivered before the surgical procedure) for women diagnosed with locally advanced breast cancer. The conclusion can have an immediate global impact over the care of women diagnosed with breast cancer. According to INCA, up to the end of 2019, 60 thousand new cases of the disease are expected to occur”, explains the oncologist.
This is a 100% Brazilian research, carried out with SUS patients. This study has no connection with the pharmaceutical industry. All stages of design and conduction of the study are carried out by the researchers themselves, and now, with support from the Cure Project, which has been helping us to raise funds to finalize the phase III”, concludes José Bines.
Presentation of clinical study
- Phase III randomized clinical study to assess the sequencing of anthracycline and taxane drugs in neoadjuvant therapy for locally advanced HER-2 negative breast cancer
- Principal Investigator: Dr. José Bines
- Coordination and management: LACOG
- Outline: Phase-III randomized clinical essay
Centers involved in the research
- INCA – Rio de Janeiro/RJ
- Hospital de Clínicas – Porto Alegre/RS
- Hospital São Lucas da PUCRS – Porto Alegre/RS
- CEPON – Florianópolis/SC
- Hospital do Amor – Barretos/SP
- ICESP – São Paulo/SP
- IBCC São Paulo SP Lilian Bastos
- Hospital Araújo Jorge – Goiânia/GO
- Grupo AMO – Salvador/BA
- HINJA – Volta Redonda/RJ
- ICT – Curitiba/PR
- Liga Norte Riograndense contra o Câncer – Natal/RN
About the Cure Project:
The Cure Project was conceived to become a transforming piece within the civil society. Its main objective is to raise funds to support the clinical researches addressing cancer in Brazil. For that purpose, the Cure works to unite science and creativity as its main tools to raise the awareness about such cause.
The initiative is linked with the Latin American Cooperative Oncology Group, LACOG, a non-for-profit organization which objective is to develop, conduct and coordinate academic studies and clinical researches in Latin America. Currently, the Cure Project works in Brazil and in a short future it will arrive in Latin America and Caribbean.